Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q3 2019 Earnings Conference Call Transcript
Nov 04, 2019 • 04:30 pm ET
Good day, everyone, and welcome to the Deciphera Pharmaceuticals Third Quarter 2019 Financial Results Conference Call.
At this time, I would like to turn the call over to Jen Robinson, Vice President and Investor Relations. Jen?
Jennifer H. Robinson
Thank you, Bill. Welcome and thank you to those of you joining us today to discuss the Deciphera's Third Quarter 2019 Financial Results. I'm Jen Robinson, Vice President, Investor Relations, at Deciphera. With me this afternoon to discuss the quarter's results and provide a general corporate update is Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management, made pursuant to Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include the status of and our expected timelines for our preclinical and clinical studies and preparations for a potential NDA submission.
Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include the execution of clinical trials, the timing of data, the actions of regulatory agencies and those set forth in our most recent quarterly report on Form 10-Q, as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the Company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steven L. Hoerter
Thank you, Jen, and good afternoon to everyone who is listening on the call and joining via the webcast. I'd like to welcome all of you to our first conference call to provide a general corporate update and financial results.
We have made significant progress across the entire pipeline over the last quarter. Most importantly, we announced positive results from our INVICTUS Pivotal Phase 3 Study of ripretinib for the treatment of advanced gastrointestinal stromal tumors or GIST. These data mark a transformative milestone for Deciphera representing our first registration enabling data set and importantly strong clinical validation of our proprietary kinase switch control inhibitor platform and the potential for our product candidates to improve the lives of people with cancer. For people living with GIST, whose disease has progressed after treatment with the currently approved drugs, there is an urgent unmet need for new therapies that can deliver effective disease control. We believe ripretinib has demonstrated the potential to transform the GIST treatment landscape and serve as an effective therapy for this heavily pre-treated patient population.
Today, we announced that the FDA has granted ripretinib Breakthrough Therapy Designation for the treatment of patients with advanced GIST